explore
Previous article:
Moonlake's readout produced a cash windfall. Risks remain
Next article: What drug price negotiations mean for Medicare Part D
Next article: What drug price negotiations mean for Medicare Part D
focus
explore
-
Listen: Biogen's potential pivot, & Illumina's next chapter
2025-10-01 01:55 -
Snackable artificial intelligence, expert AI, and the pharma industry
2025-10-01 01:06 -
What American doctors can learn from their Israeli counterparts
2025-10-01 00:48 -
Weighted lottery helped low
2025-10-01 00:04 -
Snackable artificial intelligence, expert AI, and the pharma industry
2025-10-01 00:03 -
Amylyx's ALS drug launch starts strong. It could be trouble for FDA
2025-09-30 23:44